Lanmar

EDIT - another genomics name that looks ready

做多
NASDAQ:EDIT   Editas Medicine, Inc.
All major gene editing stocks look like they're on the cusp of big moves higher. (See last post on NTLA)

Zoomed in on the shorter time frame we have a trigger off the 618 4hr retrace. There's some overhead supply in the 50s for shorter term targets, but this is a long term play with much higher upside.

Seeing similar in CRSP, but EDIT is showing a more significant breakout on the monthly time frame
Short term quick look at CRSP:

NTLA is the leader in the sector right now, but that could change fast. I am long all three
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。